Riskpilot← Back to searchSign inGet full accessWael Smith AB
ABActiveOrg 5592480304Forskningsringen 19Business and other management consultancy activities · NACE 7020Est. 20200 employees
Revenue 2025
SEK 5,6M
-96% vs 2024
EBITDA margin
-10.6%
+88% vs 2024
Equity ratio
19.7%
Financial strength
Net profit 2025
SEK 411K
+125% vs 2024
| Revenue | SEK 5,6M | -96% |
| EBITDA | SEK -593K | +88% |
| Net profit | SEK 411K | +125% |
| Total assets | SEK 2,4M | +27% |
| Equity | SEK 466K | +748% |
| Employees | 0 | — |
Legal name
Wael Smith AB
Org number
5592480304
Legal form
Aktiebolag
NACE code
7020 · Business and other management consultancy activities
Founded
16 mars 2020
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-04-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva import och export inom läkemedel, vård och detaljhandel. Bolaget skall bedriva utveckling av vårdsystem. Bolaget skall också bedriva rådgivning inom finans. Bolaget skall bedriva personaluthyrning. Bolaget ska också äga aktier och andelar i andra företag.
Address
Forskningsringen 19
Email
aw.yassir@medicarepharmacy.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | — | — | 145 663 | 5 576 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −11 | −2 | −1 | −5 040 | −593 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | −11 | −2 | −1 | −5 040 | −593 |
| Net financials | — | 5 302 | 1 643 | 559 | 5 |
| Profit before tax | −11 | 50 | 1 642 | −1 651 | 412 |
| Tax | −0 | — | — | — | −1 |
| Net profit | −11 | 50 | 1 642 | −1 651 | 411 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 1 059 | 4 155 | 6 667 | 1 863 | 2 371 |
| Equity | 14 | 64 | 1 706 | 55 | 466 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 1 045 | 4 091 | 4 961 | 1 808 | 1 905 |
| Total debt | 1 045 | 4 091 | 4 961 | 1 808 | 1 905 |
EBITDA margin
-10.6%
This company
15.8%
Market median
-167% vs market
20212025
Equity ratio
19.7%
This company
38.2%
Market median
-48% vs market
20212025
Return on equity
88.2%
This company
18.4%
Market median
+379% vs market
20212025
Net profit margin
7.4%
This company
8.1%
Market median
-9% vs market
20212025
Asset turnover
2.35×
This company
1.12×
Market median
+110% vs market
20212025
Debt / equity
4.09×
This company
0.62×
Market median
-560% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-05-01 – 2025-04-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-05-01 – 2024-04-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-05-01 – 2023-04-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-05-01 – 2022-04-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-03-01 – 2021-04-30
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
WK Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Wael Smith AB (this company)
Basonext health company ABBoard members of Wael Smith AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Wael Khedayier Yassir | Chief Executive Officer | 0 companies |
| Mejs Abdulwahid Yassir | Deputy Board Member | 0 companies |
| Lilas Yassir | Deputy Board Member | 0 companies |